↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Fischer-Cornelssen, K. A. (1984). „Fluperlapine in 104 schizophrenic patients. Open multicenter trial”. Arzneimittel-Forschung34 (1A): 125–130. PMID6145428.
↑Woggon, B.; Angst, J.; Bartels, M.; Heinrich, K.; Hippius, H.; Koukkou, M.; Krebs, E.; Küfferle, B. i dr.. (1984). „Antipsychotic efficacy of fluperlapine. An open multicenter trial”. Neuropsychobiology11 (2): 116–120. PMID6148712.
↑Dieterle, D.; Eben, E.; Einhäupl, K.; Hippius, H.; Klein, H.; Rüther, E.; Schmauß, M. (2008). „The Effect of Fluperlapine in Acute Psychotic Patients”. Pharmacopsychiatry17 (2): 57–60. DOI:10.1055/s-2007-1017408. PMID6728910.
↑Woggon, B.; Heinrich, K.; Küfferle, B.; Müller-Oerlinghausen, B.; Pöldinger, W.; Rüther, E.; Schied, H. W. (1984). „Results of a multicenter AMDP study with fluperlapine in schizophrenic patients”. Arzneimittel-Forschung34 (1A): 122–124. PMID6145427.
↑Scholz, E.; Dichgans, J. (1985). „Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine”. European archives of psychiatry and neurological sciences235 (1): 60–64. PMID2864254.
↑Pakkenberg, H.; Pedersen, B. (1985). „Medical treatment of dystonia”. Psychopharmacology. Supplementum2: 111–117. ISSN0179-8456. OCLC10642795. PMID2860654.